Clinical Trials Directory

Trials / Unknown

UnknownNCT02209311

Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate and Autologous MMSCs

Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Tissue Engineered Construction Based on a Synthetic Tricalcium Phosphate and Autologous Multipotent Mesenchymal Stromal Cells Obtained From Oral Mucosa

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation · Other Government
Sex
All
Age
20 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Autologous MMSCs will be isolated from oral mucosa biopsy sample and expanded in vitro.Tissue engineered construction will be created using synthetic tricalcium phosphate and autologous MMSCs. Patients will undergo sinus lift procedure with implantation of created tissue-engineered construction. This is a single arm study with no control. All patients receive cell therapy.

Detailed description

Patients with verified diagnosis partially edentulous maxilla and alveolar bone atrophy will undergo oral mucosa biopsy and autologous MMSCs will be derived and expanded in vitro during 3-4 weeks. After that tissue engineered construction will be created using synthetic tricalcium phosphate and autologous MMSCs. Patients will undergo sinus lift procedure with implantation of created tissue-engineered construction. Six months later patients will undergo dental implant installation. Biopsy of bone tissue at the site of sinus lift will be performed as a part of dental implant installation with subsequent histological analysis of bone specimen.

Conditions

Interventions

TypeNameDescription
PROCEDUREOral mucosa biopsy
PROCEDURESinus lift with implantation of tissue engineered construction
DEVICEDental implant

Timeline

Start date
2014-09-01
Primary completion
2017-10-01
Completion
2018-03-01
First posted
2014-08-05
Last updated
2016-11-30

Locations

2 sites across 1 country: Russia

Source: ClinicalTrials.gov record NCT02209311. Inclusion in this directory is not an endorsement.